Table 2.
Diagnostic validity metrics of the model, ILF2 protein and RBC for GC
| Cut-off value | SEN (%) |
SPE (%) |
ACC (%) |
PPV (%) |
NPV (%) |
PLR | NLR | DOR | |
|---|---|---|---|---|---|---|---|---|---|
| Model | -0.43 | ||||||||
| GC vs. Ctrl | 88.9 | 82.0 | 85.4 | 83.0 | 88.2 | 4.94 | 0.14 | 35.29 | |
| GC vs. BGD | 88.9 | 71.4 | 83.1 | 86.3 | 76.1 | 3.11 | 0.16 | 19.44 | |
| GC vs. HC | 88.9 | 92.2 | 90.0 | 95.7 | 81.0 | 11.33 | 0.12 | 94.42 | |
| ILF2 | 158.30 (ng/mL) | ||||||||
| GC vs. Ctrl | 69.7 | 91.0 | 80.4 | 88.5 | 75.2 | 7.74 | 0.33 | 23.45 | |
| GC vs. BGD | 69.7 | 85.7 | 75.0 | 90.8 | 58.3 | 4.88 | 0.35 | 13.94 | |
| GC vs. HC | 69.7 | 96.1 | 78.7 | 97.2 | 62.0 | 17.77 | 0.32 | 55.53 | |
| RBC | 4.11 (×1012∕L) | ||||||||
| GC vs. Ctrl | 50.5 | 88.0 | 69.3 | 80.6 | 64.2 | 4.21 | 0.56 | 7.52 | |
| GC vs. BGD | 50.5 | 85.7 | 62.2 | 87.7 | 46.2 | 3.54 | 0.58 | 6.10 | |
| GC vs. HC | 50.5 | 90.2 | 64.0 | 90.9 | 48.4 | 5.15 | 0.55 | 9.36 |
SEN, sensitivity; SPE, specificity; ACC, accuracy; PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio. ILF2, interleukin enhancer-binding factor 2; GC, gastric cancer; Ctrl, control (BGD + HC); BGD, benign gastric disease; HC, healthy control. RBC, red blood cell